Dr Neil Edgar Falkenburg, MD | |
14 Sidehill Trail, Ennis, MT 59729 | |
(406) 570-8405 | |
Not Available |
Full Name | Dr Neil Edgar Falkenburg |
---|---|
Gender | Male |
Speciality | Psychiatry & Neurology - Psychiatry |
Location | 14 Sidehill Trail, Ennis, Montana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1861676744 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 9556 (Montana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Neil Edgar Falkenburg, MD Po Box 1629, Ennis, MT 59729-1629 Ph: (406) 570-8405 | Dr Neil Edgar Falkenburg, MD 14 Sidehill Trail, Ennis, MT 59729 Ph: (406) 570-8405 |
News Archive
In an effort to promote wellness and disease prevention to its older adult members, Universal Health Care will begin offering the Healthways SilverSneakersĀ® Fitness Program on January 1, 2011, to subscribers of their Medicare Advantage Plan in 13 states (Florida, Arizona, Georgia, Louisiana, Maryland, Mississippi, Nevada, North Carolina, Pennsylvania, South Carolina, Texas, Utah and Virginia). SilverSneakers is the nation's leading social support and exercise program designed to improve seniors' well-being and health.
Now that the enrollment period has ended, the board that runs Maryland's troubled online insurance marketplace has opted to start over with a system that worked well in Connecticut.
If counting sheep is an abstract concept, or you are unable to visualise the faces of loved ones, you could have aphantasia - a newly defined condition to describe people who are born without a "mind's eye".
The occurrence of hallucinations and delusions is associated with poorer mental health outcomes in the nonclinical general population, researchers report.
Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.
› Verified 5 days ago